Diabetic Macular Edema (DME) Clinical Trials

Find Diabetic Macular Edema (DME) Clinical Trials Near You

A Randomized, Double-Masked, Multicenter Phase 2 Study Evaluating the Efficacy, Safety, and Tolerability of Oral BGE-102 as Mono- and Combination Therapy in Participants With Center-Involved Diabetic Macular Edema

Status: Recruiting
Location: See all (16) locations...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The purpose of this study is to learn about the effects of BGE-102 on change in vision in participants with center-involved diabetic macular edema (CI-DME). BGE-102 decreases inflammation which may improve vision or slow the progression of vison loss in those with CI-DME. Participants will be randomized to one of 3 arms and receive either BGE-102 in combination with an anti-vascular endothelial growth factor (anti-VEGF) drug, BGE-102 in combination with sham injection, or BGE-102 placebo in combination with an anti-VEGF drug. This study will also evaluate safety and tolerability of BGE-102.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Adults 18-75 years of age

• Type 1 or Type 2 Diabetes diagnosis

• Diabetic Macular Edema (DME) affecting the center of vision

• Study Eye may be treatment naïve (never received treatment) or previously treated and if previously treated, meets washout requirements

• Acceptable Vision as measured by an eye chart

• Visual Acuity and retinal thickness as measured by an eye scan, results meeting eligibility criteria

• Willing to use birth control, if applicable

Locations
United States
California
Site 104
RECRUITING
Bakersfield
Site 105
RECRUITING
Glendale
Site 118
RECRUITING
Mountain View
Florida
Site 128
RECRUITING
Fort Myers
Site 113
RECRUITING
South Miami
Louisiana
Site 119
RECRUITING
West Monroe
North Carolina
Site 117
RECRUITING
Cary
Site 116
RECRUITING
Wake Forest
South Carolina
Site 101
RECRUITING
Ladson
Texas
Site 111
RECRUITING
Abilene
Site 129
RECRUITING
Austin
Site 130
RECRUITING
Houston
Site 125
RECRUITING
Laredo
Site 106
RECRUITING
Mcallen
Site 110
RECRUITING
San Antonio
Site 108
RECRUITING
The Woodlands
Contact Information
Primary
Central Recruiting
bge102-004_inquiry@bioagelabs.com
866-331-7781
Time Frame
Start Date: 2026-08-21
Estimated Completion Date: 2027-12
Participants
Target number of participants: 180
Treatments
Experimental: Arm A: BGE-102 Monotherapy
BGE-102 Capsules dosed once daily in combination with Sham intravitreal injection delivered every 4 weeks
Experimental: Arm B: BGE-102 and anti-VEGF Combination Therapy
BGE-102 Capsules dosed once daily in combination with anti-VEGF intravitreal injection delivered every 4 weeks
Active_comparator: Arm C: anti-VEGF Monotherapy
Placebo Capsules dosed once daily in combination with anti-VEGF intravitreal injection delivered every 4 weeks
Sponsors
Leads: BioAge Labs, Inc.

This content was sourced from clinicaltrials.gov